The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease

Bingqing YANG; Jingya YIN; Qi WANG

doi:10.12449/JCH240124

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 147-150

PDF( 561 KB)

The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease

DOI: 10.12449/JCH240124

Center of Liver Diseases，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

National Natural Science Foundation of China (82170591)

More Information

Corresponding author: WANG Qi， wangqidl04@ccmu.edu.cn （ORCID： 0000-0002-0269-1568）
Received Date: 2023-04-17
Accepted Date: 2023-06-19
Published Date: 2024-01-23

Abstract

Abstract

Nonalcoholic fatty liver disease （NAFLD） has gradually become the main reason affecting human liver health， and many factors are involved in the development and progression of NAFLD. Mitochondria， as the “energy factory” of cells， plays an important role in maintaining normal physiological functions. Studies have shown that hepatic mitochondrial dysfunction promotes the development and progression of NAFLD. This article briefly introduces the latest research advances in the basic characteristics and physiological function of liver mitochondria and reviews new research findings in the association of mitochondrial dysfunction with obesity， simple fatty liver disease， and nonalcoholic steatohepatitis， in order to provide new ideas for the research on targeted mitochondrial therapy for NAFLD.
- Non-alcoholic Fatty Liver Disease,
- Mitochondria， Liver,
- Oxidative Phosphorylation,
- Mitochondrial Diseases

FullText(HTML)

References(39)

References

[1]	TARGHER G, COREY KE, BYRNE CD, et al. The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 9): 599- 612. DOI: 10.1038/s41575-021-00448-y.
[2]	PAFILI K, RODEN M. Nonalcoholic fatty liver disease(NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
[3]	RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
[4]	NOUREDDIN M, SANYAL AJ. Pathogenesis of NASH: The impact of multiple pathways[J]. Curr Hepatol Rep, 2018, 17( 4): 350- 360. DOI: 10.1007/s11901-018-0425-7.
[5]	MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155( 3): 629- 647. DOI: 10.1053/j.gastro.2018.06.083.
[6]	CIAULA AD, PASSARELLA S, SHANMUGAM H, et al. Nonalcoholic fatty liver disease(NAFLD). Mitochondria as players and targets of therapies?[J]. Int J Mol Sci, 2021, 22( 10): 5375. DOI: 10.3390/ijms22105375.
[7]	XIAO WC, AN W. Role of mitochondrial injury in the development and progression of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 7): 1515- 1521. DOI: 10.3969/j.issn.1001-5256.2021.07.005. 肖卫纯, 安威. 线粒体损伤在非酒精性脂肪性肝病发生发展中的作用[J]. 临床肝胆病杂志, 2021, 37( 7): 1515- 1521. DOI: 10.3969/j.issn.1001-5256.2021.07.005.
[8]	TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375( 6586): 1254- 1261. DOI: 10.1126/science.abf0529.
[9]	NI HM, WILLIAMS JA, DING WX. Mitochondrial dynamics and mitochondrial quality control[J]. Redox Biol, 2015, 4: 6- 13. DOI: 10.1016/j.redox.2014.11.006.
[10]	YOULE RJ, van DER BLIEK AM. Mitochondrial fission, fusion, and stress[J]. Science, 2012, 337( 6098): 1062- 1065. DOI: 10.1126/science.1219855.
[11]	CHOWANADISAI W, BAUERLY KA, TCHAPARIAN E, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression[J]. J Biol Chem, 2010, 285( 1): 142- 152. DOI: 10.1074/jbc.M109.030130.
[12]	KOLIAKI C, RODEN M. Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus[J]. Annu Rev Nutr, 2016, 36: 337- 367. DOI: 10.1146/annurev-nutr-071715-050656.
[13]	XIAN HX, LIOU YC. Functions of outer mitochondrial membrane proteins: Mediating the crosstalk between mitochondrial dynamics and mitophagy[J]. Cell Death Differ, 2021, 28( 3): 827- 842. DOI: 10.1038/s41418-020-00657-z.
[14]	KOLIAKI C, SZENDROEDI J, KAUL K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis[J]. Cell Metab, 2015, 21( 5): 739- 746. DOI: 10.1016/j.cmet.2015.04.004.
[15]	POUSSIN C, IBBERSON M, HALL D, et al. Oxidative phosphorylation flexibility in the liver of mice resistant to high-fat diet-induced hepatic steatosis[J]. Diabetes, 2011, 60( 9): 2216- 2224. DOI: 10.2337/db11-0338.
[16]	PETERSEN KF, BEFROY DE, DUFOUR S, et al. Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by(13)C magnetic resonance spectroscopy[J]. Cell Metab, 2016, 24( 1): 167- 171. DOI: 10.1016/j.cmet.2016.06.005.
[17]	SUNNY NE, PARKS EJ, BROWNING JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease[J]. Cell Metab, 2011, 14( 6): 804- 810. DOI: 10.1016/j.cmet.2011.11.004.
[18]	PEDERSEN JS, RYGG MO, CHRØIS K, et al. Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration[J]. Nat Commun, 2022, 13( 1): 2931. DOI: 10.1038/s41467-022-30629-5.
[19]	SATAPATI S, KUCEJOVA B, DUARTE JAG, et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver[J]. J Clin Invest, 2016, 126( 4): 1605. DOI: 10.1172/JCI86695.
[20]	SHAMI GJ, CHENG D, VERHAEGH P, et al. Three-dimensional ultrastructure of giant mitochondria in human non-alcoholic fatty liver disease[J]. Sci Rep, 2021, 11( 1): 3319. DOI: 10.1038/s41598-021-82884-z.
[21]	XU ZX, LUO SZ, XU MY. Mechanism of mitochondrial dysfunction in the development of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36( 10): 2353- 2355. DOI: 10.3969/j.issn.1001-5256.2020.10.042. 徐梓馨, 罗声政, 徐铭益. 线粒体功能异常在非酒精性脂肪性肝病发生中的机制[J]. 临床肝胆病杂志, 2020, 36( 10): 2353- 2355. DOI: 10.3969/j.issn.1001-5256.2020.10.042.
[22]	LI YF, XU JY, LU YT, et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing[J]. Cell Metab, 2021, 33( 10): 2004- 2020. DOI: 10.1016/j.cmet.2021.09.008.
[23]	CHAVIN KD, YANG S, LIN HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion[J]. J Biol Chem, 1999, 274( 9): 5692- 5700. DOI: 10.1074/jbc.274.9.5692.
[24]	CORTEZ-PINTO H, CHATHAM J, CHACKO VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study[J]. JAMA, 1999, 282( 17): 1659- 1664. DOI: 10.1001/jama.282.17.1659.
[25]	MORRIS EM, RECTOR RS, THYFAULT JP, et al. Mitochondria and redox signaling in steatohepatitis[J]. Antioxid Redox Signal, 2011, 15( 2): 485- 504. DOI: 10.1089/ars.2010.3795.
[26]	BEGRICHE K, IGOUDJIL A, PESSAYRE D, et al. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it[J]. Mitochondrion, 2006, 6( 1): 1- 28. DOI: 10.1016/j.mito.2005.10.004.
[27]	XU JS, CHEN SY, WANG W, et al. Hepatic CDP-diacylglycerol synthase 2 deficiency causes mitochondrial dysfunction and promotes rapid progression of NASH and fibrosis[J]. Sci Bull, 2022, 67( 3): 299- 314. DOI: 10.1016/j.scib.2021.10.014.
[28]	MIYAO M, KAWAI C, KOTANI H, et al. Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis[J]. Hepatol Res, 2022, 52( 12): 1020- 1033. DOI: 10.1111/hepr.13832.
[29]	MONTEIRO JP, OLIVEIRA PJ, JURADO AS. Mitochondrial membrane lipid remodeling in pathophysiology: A new target for diet and therapeutic interventions[J]. Prog Lipid Res, 2013, 52( 4): 513- 528. DOI: 10.1016/j.plipres.2013.06.002.
[30]	MAGKOS F, SU X, BRADLEY D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects[J]. Gastroenterology, 2012, 142( 7): 1444- 1446. DOI: 10.1053/j.gastro.2012.03.003.
[31]	APOSTOLOPOULOU M, GORDILLO R, KOLIAKI C, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis[J]. Diabetes Care, 2018, 41( 6): 1235- 1243. DOI: 10.2337/dc17-1318.
[32]	OOI GJ, MEIKLE PJ, HUYNH K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 75( 3): 524- 535. DOI: 10.1016/j.jhep.2021.04.013.
[33]	GAO RX, LI Y, XU ZM, et al. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 78( 6): 1800- 1815. DOI: 10.1097/HEP.0000000000000279.
[34]	LI Y, XIU WJ, XU JW, et al. Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling[J]. JCI Insight, 2022, 7( 23): e162402. DOI: 10.1172/jci.insight.162402.
[35]	HE YH, ZHU MX, LIU YY, et al. Research progress of Curcumin and Resveratrol in the treatment of non-alcoholic fatty liver disease[J]. Chin Med Herald, 2023, 20( 1): 57- 60. DOI: 10.20047/j.issn1673-7210.2023.01.12. 贺玉慧, 朱铭星, 刘跃洋, 等. 姜黄素与白藜芦醇治疗非酒精性脂肪性肝病的机制研究进展[J]. 中国医药导报, 2023, 20( 1): 57- 60. DOI: 10.20047/j.issn1673-7210.2023.01.12.
[36]	GEORGIEV A, GRANATA C, RODEN M. The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans[J]. Am J Physiol Cell Physiol, 2022, 322( 6): C1248- C1259. DOI: 10.1152/ajpcell.00035.2022.
[37]	GRANATA C, JAMNICK NA, BISHOP DJ. Training-induced changes in mitochondrial content and respiratory function in human skeletal muscle[J]. Sports Med, 2018, 48( 8): 1809- 1828. DOI: 10.1007/s40279-018-0936-y.
[38]	THIETART S, RAUTOU PE. Extracellular vesicles as biomarkers in liver diseases: A clinician’s point of view[J]. J Hepatol, 2020, 73( 6): 1507- 1525. DOI: 10.1016/j.jhep.2020.07.014.
[39]	AMIR DACHE Z AL, OTANDAULT A, TANOS R, et al. Blood contains circulating cell-free respiratory competent mitochondria[J]. FASEB J, 2020, 34( 3): 3616- 3630. DOI: 10.1096/fj.201901917RR.

Relative Articles

[1]	Xingtong LI, Taicheng ZHOU. Molecular mechanisms of the interaction between hepatitis B virus infection and mitochondrial homeostasis[J]. Journal of Clinical Hepatology, 2025, 41(2): 343-348. doi: 10.12449/JCH250222
[2]	Rongjun LI, Chunxia XU, Ting ZHANG, Zhihong ZHANG, Lyu WANG. Role of salidroside in a mouse model of non-alcoholic fatty liver disease： A study based on nicotinamide phosphoribosyltransferase[J]. Journal of Clinical Hepatology, 2024, 40(1): 64-69. doi: 10.12449/JCH240112
[3]	Ce ZHANG, Jiarui MIAO, Xu FAN. The role of circadian clock-controlled mitochondrial dynamics in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(8): 1670-1676. doi: 10.12449/JCH240826
[4]	Fangfang QIAN, Meiqing DAI, Li ZHAO, Xia DENG, Ling YANG, Jue JIA, Jifang WANG, Dong WANG, Guoyue YUAN. Association between serum alkaline phosphatase and type 2 diabetes mellitus with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 83-88. doi: 10.3969/j.issn.1001-5256.2023.01.013
[5]	Sutong LIU, Lihui ZHANG, Yajiao GU, Minghao LIU, Min GUO, Chenlu ZHAO, Wenxia ZHAO. Effect of Huatan Qushi Huoxue prescription on the ultrastructure of hepatocyte mitochondria in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1780-1783. doi: 10.3969/j.issn.1001-5256.2022.08.012
[6]	Jing ZHOU, Dexin ZHANG. Research advances in active components of traditional Chinese medicine in prevention and treatment of nonalcoholic fatty liver disease based on oxidative stress[J]. Journal of Clinical Hepatology, 2021, 37(12): 2951-2956. doi: 10.3969/j.issn.1001-5256.2021.12.046
[7]	Pinhua LI, Xudong LIU, Lu HUANG, Humin ZHU, Tiexiong WU, Huazhen PANG. Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2558-2561. doi: 10.3969/j.issn.1001-5256.2021.11.015
[8]	Luying ZHU, Yuchen LI, Lihua DENG, Jingtong WANG. Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2215-2219. doi: 10.3969/j.issn.1001-5256.2021.09.043
[9]	Tianying CAI, Meizhou HUANG, Hao CHEN, Baolin QIAN, Wenguang FU. Mechanism of action of mitochondrial disorders in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1953-1956. doi: 10.3969/j.issn.1001-5256.2021.08.045
[10]	Weichun XIAO, Wei AN. Role of mitochondrial injury in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1515-1521. doi: 10.3969/j.issn.1001-5256.2021.07.005
[11]	Zhang Qing, Liu ShouSheng, Sun BaoKai, Zhang Mei, Xin YongNing. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha rs8192678 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2035-2039. doi: 10.3969/j.issn.1001-5256.2020.09.025
[12]	Wang Fan, Sun Wu, Ma YuLin, Jiang HongJun. Association between microRNA-155/SH2-containing inositol phosphatase-1 and cardiovascular events in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1325-1329. doi: 10.3969/j.issn.1001-5256.2020.06.027
[13]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[14]	Zhang Hao, Zhang Yue, Zhao WenWu, Zhang JingGe. PINK1/Parkin-mediated mitophagy and its mechanism of action in the development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(7): 1663-1665. doi: 10.3969/j.issn.1001-5256.2020.07.048
[15]	Lu XiaoLiang, Jiang YuanYe, Cao Qin. The role of oxidative stress and nuclear factor erythroid 2-related factor 2 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 924-927. doi: 10.3969/j.issn.1001-5256.2020.04.048
[16]	FENG Gong, YAN QinQin, HE Na, MI Man. From nonalcoholic fatty liver disease to metabolic fatty liver disease:An analysis based on disease heterogeneity[J]. Journal of Clinical Hepatology, 2020, 36(11): 2597-2600. doi: 10.3969/j.issn.1001-5256.2020.11.045
[17]	Xu ZiXin, Luo ShengZheng, Xu MingYi. Mechanism of mitochondrial dysfunction in the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2353-2355. doi: 10.3969/j.issn.1001-5256.2020.10.042
[18]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[19]	Zhou ZhenHua, Wang LingTai, Gao YueQiu. Role of hepatocyte mitophagy in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2809-2811. doi: 10.3969/j.issn.1001-5256.2019.12.036
[20]	Zhou Fan, Peng JunWei, Fan FuGang, Jiang YuanYe, Cao Qin. Interrelation between autophagy and oxidative stress in pathogenesis of nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2018, 34(8): 1805-1808. doi: 10.3969/j.issn.1001-5256.2018.08.048

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 薄佳琪，郭子朋，刘立新. 铁死亡、双硫死亡相关的非酒精性脂肪性肝病诊断标志物筛选及诊断模型构建. 中华实验外科杂志. 2024(10): 2223-2225 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (842) PDF downloads(177)

The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease

DOI: 10.12449/JCH240124

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The mechanism of action of mitochondrial dysfunction in the development of non-alcoholic fatty liver disease

DOI: 10.12449/JCH240124

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content